

Data Sharing Statement

Mooradian. Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non–Small Cell Lung Cancer. *JAMA Netw Open*. Published April 22, 2024.
doi:10.1001/jamanetworkopen.2024.7542

Data

Data available: Yes

Data types: Deidentified participant data

How to access data: The data underlying the findings of this study were originated by Flatiron Health, Inc. These deidentified data may be made available upon request and are subject to a license agreement with Flatiron Health; interested researchers should contact DataAccess@flatiron.com to determine licensing terms. Requests to access the datasets should be directed to Flatiron Health DataAccess@flatiron.com.

When available: With publication

Supporting Documents

Document types: None

Additional Information

Who can access the data: Interested researchers (i.e. anyone requesting the data)

Types of analyses: To be determined and subject to a license agreement with Flatiron Health

Mechanisms of data availability: Without investigator support and subject to a license agreement with Flatiron Health